Trial Profile
Pharmacodynamic Study of Pembrolizumab in Patients With Recurrent Glioblastoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 13 Jan 2023
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Glioblastoma; Gliosarcoma
- Focus Therapeutic Use
- 19 Dec 2022 Planned End Date changed from 31 Dec 2022 to 31 Dec 2023.
- 06 Dec 2021 Planned End Date changed from 31 Dec 2020 to 31 Dec 2022.
- 06 Dec 2021 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2022.